COMMUNIQUÉS West-GlobeNewswire

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
29/10/2026
Peer-reviewed publication reinforces efzofitimod’s differentiated profile and potential to advance pulmonary sarcoidosis care. SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the [...]
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
29/10/2026
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile KT-579 LUMORA Phase 1b trial in lupus patients [...]
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
29/10/2026
BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Verano Announces Strong Third Quarter 2026 Financial Results Highlighted by $212 Million in Revenue and Year-Over-Year Organic Growth
29/10/2026
Company generates revenue increase of $10 million, or 5%, and highest level of cash flow from operations in four years CHICAGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“ [...]
Ligand Reports Third Quarter 2026 Financial Results
29/10/2026
Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance Conference call begins at 8: [...]
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
29/10/2026
DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage [...]
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
29/10/2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will [...]
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
29/10/2026
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
29/10/2026
Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 ZUG, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company [...]
Biosplice Executives to Appear on Health Uncensored with Dr. Drew on Sunday, November 1
29/10/2026
Chief Executive Officer Erich Horsley and Chief Medical Officer Dr. Yusuf Yazici discuss the need for innovation in knee osteoarthritis and the development of lorecivivint, which is now under regulatory review in the [...]
Fortrea Reports Third Quarter 2026 Results
29/10/2026
Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Highlights For the three months ended September 30, 2026: Revenues of $691.5 million Book-to-bill ratio [...]
MINES and Associates Earns URAC Full Accreditation for Health Utilization Management
29/10/2026
The designation demonstrates a meaningful commitment to quality health care LITTLETON, Colo., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MINES and Associates (MINES) is proud to announce that it has earned URAC Full [...]
RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call
29/10/2026
LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Helsinn announces UK MHRA approval of AKYNZEO® Oral Suspension
29/10/2026
Lugano, Switzerland – October 29 th , 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that the UK Medicines and [...]
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
29/10/2026
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond ZUG, Switzerland, October 29 th , 2026 -- Oculis [...]
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
29/10/2026
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond ZUG, Switzerland, October 29 th , 2026 -- Oculis [...]
Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform
29/10/2026
October 29, 2026 New CE-marked solution leverages the industry-leading Philips Azurion platform to integrate CT-derived insights and treatment planning directly into the procedural workflow, helping physicians make [...]
Exogenus Therapeutics leads a €13 million EU-funded consortium to advance a new secretome-based therapy for osteoarthritis
29/10/2026
ExoCordOA, a f ive-year project, led by Exogenus Therapeutics and backed by Horizon Europe, brings together ten organisations spanning biotechnology, clinical development, regulation, GMP manufacturing, imaging, [...]
ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline
29/10/2026
Financing led by Asabys, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF) Proceeds will accelerate the expansion of ALLOX’s high-throughput biophysics and AI drug discovery [...]

Pages